Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00258310 · OUTCOME

Compliance With Treatment .

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo · Source last updated 2023-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
within 365 days

What was measured

Compliance is defined as taking at least 80% of the prescribed dose for one year.

Groups in this outcome

Capecitabine

Capecitabine 1000mg/day for one year capecitabine adjuvant therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Capecitabine35

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Capecitabine74Not reported5990Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    .59
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    .90
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    param Type
    proportion
    param Value
    0.74
Complete source fields
analyses
  1. ci Lower Limit
    .59
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    .90
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    param Type
    proportion
    param Value
    0.74
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        59
        upper Limit
        90
        value
        74
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
Compliance is defined as taking at least 80% of the prescribed dose for one year.
dispersion Type
95% Confidence Interval
groups
  1. description
    Capecitabine 1000mg/day for one year capecitabine adjuvant therapy
    id
    OG000
    title
    Capecitabine
param Type
NUMBER
reporting Status
POSTED
time Frame
within 365 days
title
Compliance With Treatment .
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice